



# Maldives: Supporting COVID-19 Response and Vaccination Program

Project Name	Supporting COVID-19 Response and Vaccination Program
Project Number	55086-002
Country	Maldives
Project Status	Approved
Project Type / Modality of Assistance	Technical Assistance
Source of Funding / Amount	TA 6820-MLD: Supporting COVID-19 Response and Vaccination Program Japan Fund for Poverty Reduction US\$ 2.00 million
Strategic Agendas	Inclusive economic growth Regional integration
Drivers of Change	Knowledge solutions Partnerships
Sector / Subsector	Health - Disease control of communicable disease
Gender Equity and Mainstreaming	No gender elements
Description	To address the challenges affecting the Maldives' health system in mitigating the COVID-19 pandemic, the transaction TA will support (i) the government to rapidly strengthen its health system resilience and capacity, and (ii) developing long-term COVID-19 pandemic response and vaccination plans for expanded coverage in the upcoming years. The TA will further support the preparation of the ensuing COVID-19 vaccine financing project under APVAX
Project Rationale and Linkage to Country/Regional Strategy	The third wave of the COVID-19 pandemic revealed the vulnerabilities in the country's health system capacity that require an urgent need to improve the health systems in managing emergency medical services (EMS), strengthen coordination between health facilities, and improve the capacity to respond to COVID-19 and future pandemics. Consultations with the Ministry of Health (MOH) expressed that the vulnerabilities to be addressed immediately are due to (i) inefficient EMS for COVID-19 patients; (ii) unintegrated health information system (HIS) across health facilities, which is needed for effective COVID-19 patient information sharing during case referrals; (iii) unavailability of tracking and identifying COVID-19 variants; (iv) inadequate mental health support for COVID-19 survivors and frontline health professionals involved in COVID-19 response; and (v) lack of long-term planning for the COVID-19 pandemic response and vaccination.
Impact	
Project Outcome	
Description of Outcome	
Progress Toward Outcome	
Implementation Progress	
Description of Project Outputs	
Status of Implementation Progress (Outputs, Activities, and Issues)	
Geographical Location	Nation-wide
Summary of Environmental and Social Aspects	
Environmental Aspects	
Involuntary Resettlement	
Indigenous Peoples	
Stakeholder Communication, Participation, and Consultation	
During Project Design	
During Project Implementation	
Business Opportunities	
Consulting Services	Firm (QCBS): 18 person-months (International) and 11 person months (National) Individual (ICS): 10 person-months (International) and 54 person-months (National)
Procurement	Contracts may be procured under consultant contracts and may use competitive or direct contracting procurement method as appropriate
Responsible ADB Officer	Chen, Dai-Ling
Responsible ADB Department	South Asia Department
Responsible ADB Division	Regional Cooperation and Operations Coordination Div, SARD

Timetable	
Concept Clearance	-
Fact Finding	-
MRM	-
Approval	10 Nov 2021
Last Review Mission	-
Last PDS Update	10 Nov 2021

## TA 6820-MLD

Financing Plan/TA Utilization							Cumulative Disbursements	
ADB	Cofinancing	Counterpart				Total	Date	Amount
		Gov	Beneficiaries	Project Sponsor	Others			
0.00	2,000,000.00	0.00	0.00	0.00	0.00	2,000,000.00	-	0.00

Project Page	<a href="https://www.adb.org/projects/55086-002/main">https://www.adb.org/projects/55086-002/main</a>
Request for Information	<a href="http://www.adb.org/forms/request-information-form?subject=55086-002">http://www.adb.org/forms/request-information-form?subject=55086-002</a>
Date Generated	20 November 2021

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.